Robert Henry

Title(s)Senate Emeritus, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Epicatechin and derivatives to preserve muscle structure function in diabetes
    NIH R01DK098717Mar 10, 2014 - Dec 31, 2018
    Role: Principal Investigator
    Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin
    NIH R01AT008310Sep 1, 2013 - Aug 31, 2016
    Role: Principal Investigator
    Function of the Myo-adipo Axis in Human Obesity and Type 2 Diabetes
    NIH I01CX000635Apr 1, 2012 - Mar 31, 2016
    Role: Principal Investigator
    Role of Glycogen Synthase Kinase 3 In Type 2-Diabetes
    NIH R01DK058291Sep 1, 2001 - Jul 31, 2006
    Role: Principal Investigator
    COMPARATIVE STUDIES OF INTRACELLULAR GLUCOSE METABOLISM
    NIH R29DK038949Sep 30, 1988 - Aug 31, 1994
    Role: Principal Investigator
    General Clinical Research Center
    NIH M01RR000827Mar 1, 1974 - Nov 30, 2010
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia. Diabetes Obes Metab. 2023 07; 25(7):1985-1994. Ciaraldi TP, Boeder SC, Mudaliar SR, Giovannetti ER, Henry RR, Pettus JH. PMID: 36999233; PMCID: PMC10740106.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    2. p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes. JCI Insight. 2022 01 11; 7(1). Martins VF, LaBarge SA, Stanley A, Svensson K, Hung CW, Keinan O, Ciaraldi TP, Banoian D, Park JE, Ha C, Hetrick B, Meyer GA, Philp A, David LL, Henry RR, Aslan JE, Saltiel AR, McCurdy CE, Schenk S. PMID: 34813504; PMCID: PMC8765050.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    3. Impaired capillary tube formation induced by elevated secretion of IL8 involves altered signaling via the CXCR1/PI3K/MMP2 pathway. Mol Biol Rep. 2021 Jan; 48(1):601-610. Levy YA, Ciaraldi TP, Henry RR. PMID: 33411234.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    4. Author Correction: Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity. Nat Commun. 2020 05 05; 11(1):2276. Seo JA, Kang MC, Yang WM, Hwang WM, Kim SS, Hong SH, Heo JI, Vijyakumar A, de Moura LP, Uner A, Huang H, Lee SH, Lima IS, Park KS, Kim MS, Dagon Y, Willnow TE, Aroda V, Ciaraldi TP, Henry RR, Kim YB. PMID: 32371884; PMCID: PMC7200795.
      View in: PubMed   Mentions: 5     Fields:    
    5. Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity. Nat Commun. 2020 04 24; 11(1):2024. Seo JA, Kang MC, Yang WM, Hwang WM, Kim SS, Hong SH, Heo JI, Vijyakumar A, Pereira de Moura L, Uner A, Huang H, Lee SH, Lima IS, Park KS, Kim MS, Dagon Y, Willnow TE, Aroda V, Ciaraldi TP, Henry RR, Kim YB. PMID: 32332780; PMCID: PMC7181874.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    6. Myokine Regulation of Insulin Secretion: Impact of Inflammation and Type 2 Diabetes. Front Physiol. 2019; 10:1608. Ryan AJ, Ciaraldi TP, Henry RR. PMID: 32038288; PMCID: PMC6987462.
      View in: PubMed   Mentions: 6  
    7. Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice? Clin Diabetes. 2019 Oct; 37(4):316-337. Eckel RH, Farooki A, Henry RR, Koch GG, Leiter LA. PMID: 31660005; PMCID: PMC6794224.
      View in: PubMed   Mentions: 7  
    8. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019 Jun; 42(6):1147-1154. Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M. PMID: 30728224; PMCID: PMC6973545.
      View in: PubMed   Mentions: 117     Fields:    Translation:Humans
    9. A Pilot Study to Assess Clinical Utility and User Experience of Professional Continuous Glucose Monitoring Among People With Type 2 Diabetes. Clin Diabetes. 2019 Jan; 37(1):57-64. Midyett K, Unger JR, Wright EE, Daniel TD, Kruger DF, Henry RR, Hegazi RA. PMID: 30705498; PMCID: PMC6336116.
      View in: PubMed   Mentions: 3  
    10. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019 04; 21(4):812-821. Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, Farrell K, Sunny NE, Kalavalapalli S, Pettus J, Ciaraldi TP, Mudaliar S, Henry RR. PMID: 30447037.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    11. Correction to: Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance. Diabetologia. 2018 12; 61(12):2674. Formentini L, Ryan AJ, Gálvez-Santisteban M, Carter L, Taub P, Lapek JD, Gonzalez DJ, Villarreal F, Ciaraldi TP, Cuezva JM, Henry RR. PMID: 30324489.
      View in: PubMed   Mentions:    Fields:    
    12. Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. PLoS One. 2018; 13(9):e0203946. Henry RR, Frias JP, Walsh B, Skare S, Hemming J, Burns C, Bicsak TA, Baron A, Fineman M. PMID: 30252913; PMCID: PMC6155522.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    13. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Technol Ther. 2018 11; 20(11):715-724. Henry RR, Strange P, Zhou R, Pettus J, Shi L, Zhuplatov SB, Mansfield T, Klein D, Katz A. PMID: 30222367; PMCID: PMC6208164.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    14. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia. 2018 10; 61(10):2126-2133. McCrimmon RJ, Henry RR. PMID: 30132030; PMCID: PMC6133151.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    15. Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. Diabetes Care. 2018 08; 41(8):1792-1800. Schrieks IC, Nozza A, Stähli BE, Buse JB, Henry RR, Malmberg K, Neal B, Nicholls SJ, Rydén L, Mellbin L, Svensson A, Wedel H, Weichert A, Lincoff AM, Tardif JC, Grobbee DE, Schwartz GG. PMID: 29903845.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    16. Uromodulin mRNA from Urinary Extracellular Vesicles Correlate to Kidney Function Decline in Type 2 Diabetes Mellitus. Am J Nephrol. 2018; 47(5):283-291. Yamamoto CM, Murakami T, Oakes ML, Mitsuhashi M, Kelly C, Henry RR, Sharma K. PMID: 29779026.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    17. Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. Diabetes Obes Metab. 2018 07; 20(7):1632-1641. Henry RR, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN. PMID: 29493859; PMCID: PMC6033097.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    18. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab. 2018 06; 20(6):1479-1489. Ray KK, Leiter LA, Müller-Wieland D, Cariou B, Colhoun HM, Henry RR, Tinahones FJ, Bujas-Bobanovic M, Domenger C, Letierce A, Samuel R, Del Prato S. PMID: 29436756; PMCID: PMC5969299.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    19. A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints. Food Funct. 2018 Jan 24; 9(1):307-319. Moreno-Ulloa A, Nájera-García N, Hernández M, Ramírez-Sánchez I, Taub PR, Su Y, Beltrán-Partida E, Ceballos G, Dugar S, Schreiner G, Best BM, Ciaraldi TP, Henry RR, Villarreal F. PMID: 29171848; PMCID: PMC5783763.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    20. Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 05; 20(5):1302-1305. Pettus J, Reeds D, Cavaiola TS, Boeder S, Levin M, Tobin G, Cava E, Thai D, Shi J, Yan H, Bautista E, McMillan J, Unger R, Henry RR, Klein S. PMID: 29283470; PMCID: PMC6181222.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    21. Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study. Diabetes Care. 2018 03; 41(3):613-619. Henry RR, Rosenstock J, Denham DS, Prabhakar P, Kjems L, Baron MA. PMID: 29301824.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    22. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017 12; 19(12):1781-1792. Leiter LA, Cariou B, Müller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, Ray KK, Bujas-Bobanovic M, Domenger C, Mandel J, Samuel R, Henry RR. PMID: 28905478; PMCID: PMC5698740.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    23. Circulating ApoJ is closely associated with insulin resistance in human subjects. Metabolism. 2018 01; 78:155-166. Seo JA, Kang MC, Ciaraldi TP, Kim SS, Park KS, Choe C, Hwang WM, Lim DM, Farr O, Mantzoros C, Henry RR, Kim YB. PMID: 28986164; PMCID: PMC5765540.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    24. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017 12 14; 377(24):2337-2348. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Simó R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. PMID: 28899222.
      View in: PubMed   Mentions: 149     Fields:    Translation:HumansCTClinical Trials
    25. Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance. Diabetologia. 2017 10; 60(10):2052-2065. Formentini L, Ryan AJ, Gálvez-Santisteban M, Carter L, Taub P, Lapek JD, Gonzalez DJ, Villarreal F, Ciaraldi TP, Cuezva JM, Henry RR. PMID: 28770317; PMCID: PMC6572787.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    26. Deletion of interleukin 1 receptor-associated kinase 1 (Irak1) improves glucose tolerance primarily by increasing insulin sensitivity in skeletal muscle. J Biol Chem. 2017 07 21; 292(29):12339-12350. Sun XJ, Kim SP, Zhang D, Sun H, Cao Q, Lu X, Ying Z, Li L, Henry RR, Ciaraldi TP, Taylor SI, Quon MJ. PMID: 28572512; PMCID: PMC5519380.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    27. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovasc Diabetol. 2017 05 25; 16(1):70. Müller-Wieland D, Leiter LA, Cariou B, Letierce A, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M. PMID: 28545518; PMCID: PMC5445362.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    28. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab. 2017 06; 19(6):814-821. Henry RR, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L. PMID: 28098426.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    29. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. Age (Dordr). 2016 Dec; 38(5-6):485-493. Espinoza SE, Wang CP, Tripathy D, Clement SC, Schwenke DC, Banerji MA, Bray GA, Buchanan TA, Henry RR, Kitabchi AE, Mudaliar S, Stentz FB, Reaven PD, DeFronzo RA, Musi N. PMID: 27585671; PMCID: PMC5266219.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    30. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study. Diabetes Technol Ther. 2016 11; 18(11):677-686. Henry RR, Klein EJ, Han J, Iqbal N. PMID: 27525540; PMCID: PMC5124747.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    31. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J. 2016 Oct 14; 37(39):2981-2989. Colhoun HM, Ginsberg HN, Robinson JG, Leiter LA, Müller-Wieland D, Henry RR, Cariou B, Baccara-Dinet MT, Pordy R, Merlet L, Eckel RH. PMID: 27460890; PMCID: PMC5081037.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    32. Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes. PLoS One. 2016; 11(7):e0158209. Ciaraldi TP, Ryan AJ, Mudaliar SR, Henry RR. PMID: 27453994; PMCID: PMC4959771.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    33. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016; 10:1299-307. Polonsky WH, Henry RR. PMID: 27524885; PMCID: PMC4966497.
      View in: PubMed   Mentions: 267  
    34. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016 Jul; 39(7):1115-22. Mudaliar S, Alloju S, Henry RR. PMID: 27289124.
      View in: PubMed   Mentions: 249     Fields:    Translation:Humans
    35. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract. 2016 Jun; 22(6):753-62. Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR. PMID: 27082665.
      View in: PubMed   Mentions: 125     Fields:    
    36. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. Diabetes Care. 2016 Apr; 39(4):532-8. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. PMID: 26989182.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    37. Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. J Clin Endocrinol Metab. 2016 05; 101(5):2056-62. Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA. PMID: 26982008; PMCID: PMC6287507.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    38. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016 Jan; 22(1):84-113. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE). PMID: 26731084.
      View in: PubMed   Mentions: 166     Fields:    Translation:Humans
    39. Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside. Diabetes Care. 2015 Dec; 38(12):2344-53. Mudaliar S, Polidori D, Zambrowicz B, Henry RR. PMID: 26604280.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimals
    40. Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management "Tune Up" Clinic in Complex Patients. Ann Pharmacother. 2016 Jan; 50(1):8-16. Morello CM, Christopher ML, Ortega L, Khoan J, Rotunno T, Edelman SV, Henry RR, Hirsch JD. PMID: 26546580.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    41. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care. 2015 Dec; 38(12):2258-65. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. PMID: 26486192.
      View in: PubMed   Mentions: 104     Fields:    Translation:HumansCTClinical Trials
    42. Activation of G proteins by GIV-GEF is a pivot point for insulin resistance and sensitivity. Mol Biol Cell. 2015 Nov 15; 26(23):4209-23. Ma GS, Lopez-Sanchez I, Aznar N, Kalogriopoulos N, Pedram S, Midde K, Ciaraldi TP, Henry RR, Ghosh P. PMID: 26378251; PMCID: PMC4642855.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    43. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015 07 23; 1:15019. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R. PMID: 27189025.
      View in: PubMed   Mentions: 749     Fields:    Translation:HumansCells
    44. Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes. Diabetes Care. 2015 Jul; 38(7):1189-96. Eckel RH, Henry RR, Yue P, Dhalla A, Wong P, Jochelson P, Belardinelli L, Skyler JS. PMID: 26049552; PMCID: PMC4477340.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    45. Excessive secretion of IL-8 by skeletal muscle in type 2 diabetes impairs tube growth: potential role of PI3K and the Tie2 receptor. Am J Physiol Endocrinol Metab. 2015 Jul 01; 309(1):E22-34. Amir Levy Y, Ciaraldi TP, Mudaliar SR, Phillips SA, Henry RR. PMID: 25944879.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    46. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015 Apr; 21 Suppl 1:1-87. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovic L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. PMID: 25869408; PMCID: PMC4959114.
      View in: PubMed   Mentions: 247     Fields:    
    47. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocr Pract. 2015 Apr; 21(4):413-37. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovic L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. PMID: 27408942.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    48. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. J Clin Endocrinol Metab. 2015 May; 100(5):1855-62. Tripathy D, Cobb JE, Gall W, Adam KP, George T, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Reaven PD, Musi N, Ferrannini E, DeFronzo RA. PMID: 25603459; PMCID: PMC4422894.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    49. Regulation of substrate utilization by the mitochondrial pyruvate carrier. Mol Cell. 2014 Nov 06; 56(3):425-435. Vacanti NM, Divakaruni AS, Green CR, Parker SJ, Henry RR, Ciaraldi TP, Murphy AN, Metallo CM. PMID: 25458843; PMCID: PMC4267523.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansAnimalsCells
    50. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015 Mar; 38(3):412-9. Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, Bogle A, Iqbal N, List J, Griffen SC. PMID: 25271207.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    51. Status of Diabetes Care: "It just doesn't get any better . . . or does it?". Diabetes Care. 2014 Jul; 37(7):1782-5. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry RR, Hill Golden S, Rich S, Reynolds L. PMID: 25093231; PMCID: PMC5131856.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    52. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care. 2014 Sep; 37(9):2609-15. Henry RR, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen N, Sinha VP, Linnebjerg H. PMID: 24947791.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    53. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014 Apr 16; 311(15):1515-25. Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE, AleCardio Investigators. PMID: 24682069.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCTClinical Trials
    54. Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care. 2014 Jul; 37(7):1918-23. DePaoli AM, Higgins LS, Henry RR, Mantzoros C, Dunn FL, INT131-007 Study Group. PMID: 24722496.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    55. Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. Diabetes Care. 2014 Jun; 37(6):1706-11. Tripathy D, Clement SC, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA. PMID: 24705615; PMCID: PMC4179517.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    56. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014 May-Jun; 28(3):399-405. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. PMID: 24561125; PMCID: PMC4231710.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    57. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications. 2014 May-Jun; 28(3):393-8. Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA. PMID: 24631129.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    58. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014 Mar; 16(3):137-44. Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Duchesne D, Iqbal N, List J. PMID: 24237386.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    59. Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation. J Nutr Biochem. 2014 Jan; 25(1):91-4. Gutierrez-Salmean G, Ciaraldi TP, Nogueira L, Barboza J, Taub PR, Hogan MC, Henry RR, Meaney E, Villarreal F, Ceballos G, Ramirez-Sanchez I. PMID: 24314870; PMCID: PMC3857584.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimals
    60. Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa. Clin Sci (Lond). 2013 Oct; 125(8):383-9. Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Gonzalez-Basurto S, Coral-Vazquez R, Perkins G, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. PMID: 23642227.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    61. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care. 2013 Nov; 36(11):3607-12. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, Gastaldelli A, ACT NOW Study. PMID: 24062330; PMCID: PMC3816921.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    62. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. Metabolism. 2013 Nov; 62(11):1587-96. Ciaraldi TP, Aroda V, Mudaliar SR, Henry RR. PMID: 23958241.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    63. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. Am Heart J. 2013 Sep; 166(3):429-34. Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Rydén L, Schwartz GG, Malmberg K, Buse JB, Henry RR, Wedel H, Weichert A, Cannata R, Grobbee DE. PMID: 24016490.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    64. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013 Nov; 62(11):3920-6. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, ACT NOW Study. PMID: 23863810; PMCID: PMC3806596.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    65. (-)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients. Int J Cardiol. 2013 Oct 09; 168(4):3982-3990. Ramirez-Sanchez I, Taub PR, Ciaraldi TP, Nogueira L, Coe T, Perkins G, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. PMID: 23870648; PMCID: PMC3805662.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCTClinical Trials
    66. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013 Aug; 98(8):3446-53. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. PMID: 23733372.
      View in: PubMed   Mentions: 111     Fields:    Translation:Humans
    67. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013 Sep; 145(3):574-82.e1. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. PMID: 23727264.
      View in: PubMed   Mentions: 399     Fields:    Translation:Humans
    68. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications. 2013 Sep-Oct; 27(5):508-18. Henry RR, Chilton R, Garvey WT. PMID: 23726071; PMCID: PMC4139280.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    69. Signals and noise in drug safety analyses: the incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance. Diabetes Care. 2013 Jul; 36(7):1804-6. Cefalu WT, Rosenstock J, Henry RR, Riddle M. PMID: 23695816; PMCID: PMC3687287.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. Adipocyte. 2013 Oct 01; 2(4):217-26. Meyer LK, Ciaraldi TP, Henry RR, Wittgrove AC, Phillips SA. PMID: 24052897; PMCID: PMC3774697.
      View in: PubMed   Mentions: 73     Fields:    
    71. Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes. Diabetes Care. 2013 Sep; 36(9):2559-65. Henry RR, Rosenstock J, Logan DK, Alessi TR, Luskey K, Baron MA. PMID: 23645886; PMCID: PMC3747935.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    72. Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature. Expert Rev Endocrinol Metab. 2013 May; 8(3):247-259. Tibble CA, Cavaiola TS, Henry RR. PMID: 30780817.
      View in: PubMed   Mentions: 8     Fields:    
    73. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes. Clin Ther. 2013 May; 35(5):634-645.e1. Henry RR, Logan D, Alessi T, Baron MA. PMID: 23578605.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    74. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A. 2013 Apr 02; 110(14):5422-7. Divakaruni AS, Wiley SE, Rogers GW, Andreyev AY, Petrosyan S, Loviscach M, Wall EA, Yadava N, Heuck AP, Ferrick DA, Henry RR, McDonald WG, Colca JR, Simon MI, Ciaraldi TP, Murphy AN. PMID: 23513224; PMCID: PMC3619368.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansAnimalsCells
    75. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013 Aug; 36(8):2154-61. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry RR. PMID: 23412078; PMCID: PMC3714520.
      View in: PubMed   Mentions: 108     Fields:    Translation:Humans
    76. Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes. Curr Cardiol Rep. 2013 Feb; 15(2):332. Taub PR, Higginbotham E, Henry RR. PMID: 23314689.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    77. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013 Jan-Feb; 19(1):107-16. Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapiador CD, Weyer C, American Association of Clinical Endocrinologists. PMID: 23435042; PMCID: PMC4108221.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    78. Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase. Proc Natl Acad Sci U S A. 2013 Jan 02; 110(1):E79-88. He Z, Zhu HH, Bauler TJ, Wang J, Ciaraldi T, Alderson N, Li S, Raquil MA, Ji K, Wang S, Shao J, Henry RR, King PD, Feng GS. PMID: 23236157; PMCID: PMC3538237.
      View in: PubMed   Mentions: 29     Fields:    Translation:AnimalsCells
    79. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013 Feb; 33(2):393-9. Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Tripathy D, DeFronzo RA, Reaven PD. PMID: 23175674; PMCID: PMC3908828.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    80. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care. 2012 Nov; 35(11):2198-200. Mudaliar S, Armstrong DA, Mavian AA, O'Connor-Semmes R, Mydlow PK, Ye J, Hussey EK, Nunez DJ, Henry RR, Dobbins RL. PMID: 23011728; PMCID: PMC3476920.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    81. Thiazolidinedione safety. Expert Opin Drug Saf. 2012 Jul; 11(4):565-79. Kung J, Henry RR. PMID: 22616948.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    82. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012 Jun; 34(6):1247-1258.e22. Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, Hoogwerf BJ. PMID: 22608780.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    83. A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature. 2012 May 17; 485(7398):391-4. Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, He M, Juguilon H, Yin YQ, Phillips CT, Yu RT, Olefsky JM, Henry RR, Downes M, Evans RM. PMID: 22522926; PMCID: PMC3358516.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansAnimalsCells
    84. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. J Clin Endocrinol Metab. 2012 Jul; 97(7):2370-9. Henry RR, Mudaliar S, Kanitra L, Woloschak M, Balena R, T-Emerge 3 Study Group. PMID: 22539590.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    85. Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. Clin Sci (Lond). 2012 Feb; 122(4):193-202. Perlstein TS, Henry RR, Mather KJ, Rickels MR, Abate NI, Grundy SM, Mai Y, Albu JB, Marks JB, Pool JL, Creager MA. PMID: 21861845; PMCID: PMC4566948.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    86. Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci. 2012 Feb; 5(1):43-7. Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Perkins G, Murphy AN, Naviaux R, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. PMID: 22376256; PMCID: PMC5439909.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansAnimalsCells
    87. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Endocr Pract. 2011 Nov-Dec; 17(6):906-13. Henry RR, Buse JB, Sesti G, Davies MJ, Jensen KH, Brett J, Pratley RE. PMID: 22193143.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    88. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011 Mar 24; 364(12):1104-15. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD, ACT NOW Study. PMID: 21428766.
      View in: PubMed   Mentions: 274     Fields:    Translation:Humans
    89. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest. 2011 Mar; 121(3):918-29. Jin W, Goldfine AB, Boes T, Henry RR, Ciaraldi TP, Kim EY, Emecan M, Fitzpatrick C, Sen A, Shah A, Mun E, Vokes V, Schroeder J, Tatro E, Jimenez-Chillaron J, Patti ME. PMID: 21393865; PMCID: PMC3049368.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCells
    90. In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes. Am J Physiol Endocrinol Metab. 2011 Mar; 300(3):E536-42. Chun KH, Choi KD, Lee DH, Jung Y, Henry RR, Ciaraldi TP, Kim YB. PMID: 21189360; PMCID: PMC3064006.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    91. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010 Jul; 9(7):551-9. Chao EC, Henry RR. PMID: 20508640.
      View in: PubMed   Mentions: 241     Fields:    Translation:HumansAnimals
    92. Sedentary aging increases resting and exercise-induced intramuscular free radical formation. J Appl Physiol (1985). 2010 Aug; 109(2):449-56. Bailey DM, McEneny J, Mathieu-Costello O, Henry RR, James PE, McCord JM, Pietri S, Young IS, Richardson RS. PMID: 20507973; PMCID: PMC2928589.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    93. Managing type 2 diabetes: balancing HbA1c and body weight. Postgrad Med. 2010 May; 122(3):106-17. Mavian AA, Miller S, Henry RR. PMID: 20463420.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    94. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med. 2010 Mar; 123(3 Suppl):S19-27. Mudaliar S, Henry RR. PMID: 20206728.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    95. Pharmacotherapy of hyperglycemia. Expert Opin Pharmacother. 2009 Oct; 10(15):2415-32. Kulasa KM, Henry RR. PMID: 19743938.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    96. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009 Jul 29; 9:17. Defronzo RA, Banerji M, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner R, Reaven PD, Schwenke D, Stentz FB, Tripathy D. PMID: 19640291; PMCID: PMC2725044.
      View in: PubMed   Mentions: 24     Fields:    
    97. Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab. 2009 Sep; 297(3):E767-73. Phillips SA, Kung J, Ciaraldi TP, Choe C, Christiansen L, Mudaliar S, Henry RR. PMID: 19622782; PMCID: PMC2739702.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsCTClinical Trials
    98. Incretin therapies: effects beyond glycemic control. Eur J Intern Med. 2009 Jul; 20 Suppl 2:S319-28. Mudaliar S, Henry RR. PMID: 19580951.
      View in: PubMed   Mentions: 4  Translation:HumansAnimalsCells
    99. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009 Jul 11; 374(9684):126-35. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. PMID: 19515415.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    100. Incretin therapies: effects beyond glycemic control. Am J Med. 2009 Jun; 122(6 Suppl):S25-36. Mudaliar S, Henry RR. PMID: 19464425.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    101. The role of incretins in cardiovascular control. Curr Hypertens Rep. 2009 Feb; 11(1):18-22. Mafong DD, Henry RR. PMID: 19146796.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    102. Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids. Endocrine. 2009 Feb; 35(1):38-46. Phillips PS, Ciaraldi TP, Kim DL, Verity MA, Wolfson T, Henry RR, Scripps Mercy Clinical Research Center. PMID: 19051066.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    103. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2009 Feb; 94(2):469-76. Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, Chang RJ, Henry RR. PMID: 18984667; PMCID: PMC2646515.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    104. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab. 2009 Jan; 94(1):157-63. Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry RR. PMID: 18854391; PMCID: PMC2630871.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    105. Response of adiponectin and its receptors to changes in metabolic state after gastric bypass surgery: dissociation between adipose tissue expression and circulating levels. Surg Obes Relat Dis. 2009 Mar-Apr; 5(2):172-80. Savu MK, Phillips SA, Oh DK, Park K, Gerlan C, Ciaraldi TP, Henry RR. PMID: 18996753.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    106. Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab. 2008 Oct; 295(4):E842-50. Phillips SA, Ciaraldi TP, Oh DK, Savu MK, Henry RR. PMID: 18664597; PMCID: PMC2575897.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    107. Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease. Curr Med Res Opin. 2008 Aug; 24(8):2189-202. Henry RR. PMID: 18573228.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    108. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008 Mar; 6(3):343-68. Bays HE, González-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR. PMID: 18327995.
      View in: PubMed   Mentions: 175     Fields:    Translation:HumansCells
    109. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep. 2008 Feb; 10(1):55-60. Mafong DD, Henry RR. PMID: 18366986.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    110. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril. 2008 May; 89(5):1200-1208. Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry RR. PMID: 17706206; PMCID: PMC7027432.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    111. Role of glycogen synthase kinase-3 alpha in insulin action in cultured human skeletal muscle cells. Endocrinology. 2007 Sep; 148(9):4393-9. Ciaraldi TP, Nikoulina SE, Bandukwala RA, Carter L, Henry RR. PMID: 17569761.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    112. Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease. Diabetes Technol Ther. 2007 Jun; 9 Suppl 1:S83-92. Mudaliar S, Henry RR. PMID: 17563308.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    113. Adiponectin in health and disease. Diabetes Obes Metab. 2007 May; 9(3):282-9. Oh DK, Ciaraldi T, Henry RR. PMID: 17391153.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCells
    114. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007 Mar; 30(3):753-9. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B, American Diabetes Association. PMID: 17327355.
      View in: PubMed   Mentions: 520     Fields:    
    115. Electron paramagnetic spectroscopic evidence of exercise-induced free radical accumulation in human skeletal muscle. Free Radic Res. 2007 Feb; 41(2):182-90. Bailey DM, Lawrenson L, McEneny J, Young IS, James PE, Jackson SK, Henry RR, Mathieu-Costello O, McCord JM, Richardson RS. PMID: 17364944.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    116. Cardiometabolic risk modification: current trends and emerging therapies. JAAPA. 2006 Dec; Suppl Cardiometabolic:3-14; quiz 15-6. Lillo JL, Bray G, Woods SC, Henry RR, Hadley RD. PMID: 17354517.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    117. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev. 2006 Nov-Dec; 22(6):483-91. Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH, Kim DD, Maggs DG. PMID: 16634116.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    118. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006 Jun 15; 354(24):2552-63. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. PMID: 16775236.
      View in: PubMed   Mentions: 457     Fields:    Translation:HumansCells
    119. Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab. 2006 Nov; 291(5):E891-8. Ciaraldi TP, Oh DK, Christiansen L, Nikoulina SE, Kong AP, Baxi S, Mudaliar S, Henry RR. PMID: 16757548.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsCTClinical Trials
    120. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. J Diabetes Complications. 2006 Jan-Feb; 20(1):14-20. Fonseca VA, Theuma P, Mudaliar S, Leissinger CA, Clejan S, Henry RR. PMID: 16389162.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    121. Effect of a high-carbohydrate versus a high--cis-monounsaturated fat diet on blood pressure in patients with type 2 diabetes. Diabetes Care. 2005 Nov; 28(11):2607-12. Shah M, Adams-Huet B, Bantle JP, Henry RR, Griver KA, Raatz SK, Brinkley LJ, Reaven GM, Garg A. PMID: 16249527.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    122. Adipocyte differentiation-related protein in human skeletal muscle: relationship to insulin sensitivity. Obes Res. 2005 Aug; 13(8):1321-9. Phillips SA, Choe CC, Ciaraldi TP, Greenberg AS, Kong AP, Baxi SC, Christiansen L, Mudaliar SR, Henry RR. PMID: 16129713.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    123. Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: comparisons with insulin and insulin-like growth factor I. J Clin Endocrinol Metab. 2005 Oct; 90(10):5551-8. Ciaraldi TP, Phillips SA, Carter L, Aroda V, Mudaliar S, Henry RR. PMID: 16030168.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    124. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab. 2005 Sep; 90(9):5414-25. O'Connor DT, Cadman PE, Smiley C, Salem RM, Rao F, Smith J, Funk SD, Mahata SK, Mahata M, Wen G, Taupenot L, Gonzalez-Yanes C, Harper KL, Henry RR, Sanchez-Margalet V. PMID: 15956083.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    125. Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am J Physiol Endocrinol Metab. 2005 Jul; 289(1):E151-9. Cha BS, Ciaraldi TP, Park KS, Carter L, Mudaliar SR, Henry RR. PMID: 15727952.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsCTClinical Trials
    126. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004 Nov; 27(11):2628-35. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group. PMID: 15504997.
      View in: PubMed   Mentions: 316     Fields:    Translation:HumansCTClinical Trials
    127. Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J Clin Endocrinol Metab. 2005 Jan; 90(1):352-8. Ciaraldi TP, Mudaliar S, Barzin A, Macievic JA, Edelman SV, Park KS, Henry RR. PMID: 15483099.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    128. Diabetes and obesity: medical diseases, surgical cure? Curr Diab Rep. 2004 Oct; 4(5):317-8. Aroda VR, Savu MK, Henry RR. PMID: 15461894.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    129. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am. 2004 Sep; 33(3):595-616, vii-viii. Einhorn D, Aroda VR, Henry RR. PMID: 15262299.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    130. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2004 Sep 01; 44(5):1047-52. Bhalla MA, Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clopton P, Krishnaswamy P, Morrison LK, Chiu A, Gardetto N, Mudaliar S, Edelman SV, Henry RR, Maisel AS. PMID: 15337217.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    131. Hyperglycemia with antipsychotic treatment. Curr Diab Rep. 2004 Feb; 4(1):41-5. Sathyaprakash R, Henry RR. PMID: 14764279.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    132. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab. 2003 Dec; 88(12):5875-80. Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, Ray A, Davis T, Breier A, Henry RR, Dananberg J. PMID: 14671184.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    133. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc. 2003 Dec; 103(12):1607-12. Grotz VL, Henry RR, McGill JB, Prince MJ, Shamoon H, Trout JR, Pi-Sunyer FX. PMID: 14647086.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    134. Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol. 2003 Nov; 43(11):1228-34. Henry RR, Mudaliar S, Chu N, Kim D, Armstrong D, Davis TT, An B, Reinhardt RR. PMID: 14551177.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    135. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003 Sep-Oct; 9(5):406-16. Mudaliar S, Chang AR, Henry RR. PMID: 14583425.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    136. Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes. 2003 Aug; 52(8):1935-42. Kim YB, Kotani K, Ciaraldi TP, Henry RR, Kahn BB. PMID: 12882908.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCells
    137. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003 Aug; 26(8):2442-50. Chandran M, Phillips SA, Ciaraldi T, Henry RR. PMID: 12882876.
      View in: PubMed   Mentions: 260     Fields:    Translation:HumansAnimalsCells
    138. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metabolism. 2003 May; 52(5):540-6. Mathieu-Costello O, Kong A, Ciaraldi TP, Cui L, Ju Y, Chu N, Kim D, Mudaliar S, Henry RR. PMID: 12759881.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
    139. Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab. 2003 Aug; 285(2):E354-62. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR, Henry RR. PMID: 12700163.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    140. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care. 2003 Mar; 26(3):764-9. Henry RR, Mudaliar SR, Howland WC, Chu N, Kim D, An B, Reinhardt RR. PMID: 12610035.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    141. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003 Mar; 52(3):667-74. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR. PMID: 12606507.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCellsCTClinical Trials
    142. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003 Jan; 26(1):1-8. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR. PMID: 12502651.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    143. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin Ther. 2003; 25 Suppl B:B47-63. Henry RR. PMID: 14553866.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    144. Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep. 2002 Oct; 2(5):416-22. Sathyaprakash R, Henry RR. PMID: 12643167.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    145. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care. 2002 Sep; 25(9):1597-602. Mudaliar S, Mohideen P, Deutsch R, Ciaraldi TP, Armstrong D, Kim B, Sha X, Henry RR. PMID: 12196433.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    146. Insulin and insulin-like growth factor-1 action on human skeletal muscle: preferential effects of insulin-like growth factor-1 in type 2 diabetic subjects. Metabolism. 2002 Sep; 51(9):1171-9. Ciaraldi TP, Carter L, Rehman N, Mohideen P, Mudaliar S, Henry RR. PMID: 12200763.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    147. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes. 2002 Jul; 51(7):2190-8. Nikoulina SE, Ciaraldi TP, Mudaliar S, Carter L, Johnson K, Henry RR. PMID: 12086949.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    148. Free fatty acid metabolism in human skeletal muscle is regulated by PPARgamma and RXR agonists. Ann N Y Acad Sci. 2002 Jun; 967:66-70. Ciaraldi TP, Cha BS, Park KS, Carter L, Mudaliar SR, Henry RR. PMID: 12079836.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    149. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002 Mar; 25(3):542-9. Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD. PMID: 11874944.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    150. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes. 2002 Feb; 51(2):443-8. Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB. PMID: 11812753.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    151. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes. 2002 Jan; 51(1):30-6. Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry RR. PMID: 11756319.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    Robert's Networks
    Concepts (523)
    Derived automatically from this person's publications.
    _
    Co-Authors (44)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _